|
End-of-day quote
New Zealand S.E.
2026-09-29
|
5-day change | 1st Jan Change | ||
| 4.340 NZD | -0.23% |
|
+2.84% | +28.40% |
| 09-08 | Aft Pharmaceuticals Limited Partners with Mark Cuban Cost Plus Drug Company to Bring Combogesic to the U.S | CI |
| 07-31 | AFT Pharmaceuticals Limited - Shareholder/Analyst Call |
| Market Cap | 455M 256M 226M 214M 194M 364M 24.59B 367M 2.57B 989M 12.56B 962M 941M 40.41B | P/E 2027 * |
23.1x | P/E 2028 * | 18.3x |
|---|---|---|---|---|---|
| Enterprise Value | 485M 273M 241M 228M 207M 388M 26.2B 391M 2.74B 1.05B 13.38B 1.03B 1B 43.06B | EV / Sales 2027 * |
1.6x | EV / Sales 2028 * | 1.39x |
| Free-Float |
22.37% | Yield 2027 * |
0.75% | Yield 2028 * | 0.96% |
| Markets | Quality | ||
|---|---|---|---|
New Zealand S.E.
| AFT | End-of-day quote | |
Australian S.E.
| AFP | Delayed |
Last Transcript: AFT Pharmaceuticals Limited
| 24-01-20 | Rentevrees zet Bel20 onder druk | |
| 24-01-19 | KBC uitblinker op groene beurs | |
| 24-01-19 | Brusselse beurs opent flink hoger | |
| 24-01-19 | Brussel start handelsdag vermoedelijk in het groen | |
| 24-01-18 | Hyloris gaat samenwerken met AFT Pharmaceuticals |
| 1 day | -0.23% | ||
| 1 week | +2.84% | ||
| Current month | -2.25% | ||
| 1 month | -3.56% | ||
| 3 months | +17.30% | ||
| 6 months | +28.02% | ||
| Current year | +28.40% |
| 1 week | 4.3 |  | 4.48 |
| 1 month | 4.2 | | 4.49 |
| Current year | 3.35 | | 4.85 |
| 1 year | 2.76 | | 4.85 |
| 3 years | 2.37 | | 4.85 |
| 5 years | 2.37 | | 5 |
| 10 years | 1.7 | | 5.65 |
| Manager | Title | Age | Since |
|---|---|---|---|
Marree Atkinson
HRO | Human Resources Officer | - | 2012-09-03 |
Hartley Atkinson
CEO | Chief Executive Officer | - | 1997-09-03 |
Stuart Houliston
DFI | Director of Finance/CFO | - | 2026-06-14 |
| Director | Title | Age | Since |
|---|---|---|---|
David Flacks
CHM | Chairman | - | 2015-06-21 |
Hartley Atkinson
BRD | Director/Board Member | - | 1997-09-03 |
Marree Atkinson
BRD | Director/Board Member | - | 2012-09-03 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 7/3/25 | Buy | Founder | 200,000 | 0.1907% | ||
| 6/26/25 | Free | Founder | 17,755 | 0.0169% | ||
| 12/2/24 | Buy | Founder | 45 | 0.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.23% | +2.84% | +53.90% | +26.16% | 258M | |
| -0.01% | +1.24% | +63.06% | +120.55% | 1,056B | |
| -1.61% | -0.60% | +47.32% | +71.79% | 655B | |
| -1.12% | -0.72% | +17.98% | +76.63% | 471B | |
| -1.72% | -4.06% | +36.39% | +39.47% | 342B | |
| -0.40% | +3.83% | +22.08% | +28.82% | 277B | |
| -0.51% | -1.93% | +12.09% | +11.94% | 257B | |
| +1.32% | +3.27% | +54.63% | +57.63% | 226B | |
| -0.61% | -0.91% | +34.33% | +101.87% | 189B | |
| -0.24% | -2.76% | -28.41% | -60.92% | 170B | |
| Average | -0.19% | +0.18% | +31.34% | +47.39% | 364.31B | |
| Weighted average by Cap. | -0.05% | +0.42% | +38.91% | +70.52% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 304M 171M 151M 143M 130M 243M 16.41B 245M 1.71B 660M 8.38B 642M 628M 26.97B | 345M 194M 172M 162M 147M 276M 18.65B 279M 1.95B 750M 9.52B 730M 714M 30.65B |
| Net income | 19.7M 11.09M 9.79M 9.26M 8.4M 15.74M 1.06B 15.9M 111M 42.81M 543M 41.64M 40.73M 1.75B | 24.81M 13.97M 12.33M 11.66M 10.58M 19.83M 1.34B 20.03M 140M 53.93M 685M 52.46M 51.32M 2.2B |
| Net Debt | 29.84M 16.8M 14.82M 14.03M 12.72M 23.85M 1.61B 24.08M 168M 64.85M 823M 63.07M 61.7M 2.65B | 24.6M 13.85M 12.22M 11.56M 10.49M 19.66M 1.33B 19.85M 139M 53.46M 679M 52M 50.87M 2.18B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-29 | NZ$4.340 | -0.23% | 12,849 |
| 26-09-28 | NZ$4.350 | -0.91% | 23,403 |
| 26-09-25 | NZ$4.390 | +1.86% | 10,238 |
| 26-09-24 | NZ$4.310 | +0.23% | 7,951 |
| 26-09-23 | NZ$4.300 | +1.90% | 12,557 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Stocks
- AFT Stock
Select your edition
All financial news and data tailored to specific country editions
